^
Association details:
Biomarker:IRF1 expression
Cancer:Melanoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

Excerpt:
Transcript levels were significantly higher in responders (CR/PR/SD) than in nonresponders (PD) for CD8A (p = 0.0001) and IRF1 (p = 0.0019). PFS was strongly associated with high CD274 (p = 0.0046), PDCD1LG2 (p = 0.0039), CD8A (p = 0.0002), and IRF1 (p = 0.0030) mRNA expression.
DOI:
https://doi.org/10.1186/s40425-019-0731-9